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In basic principle, the most common surgical treatments 
for glaucoma involve bypassing trabecular meshwork 
resistance by rou ting aqueous humor d irectly to the 
subconjunctival space. Modernday trabeculectomy is 
the most common penetrating surgery for glaucoma. 
The m ost  recogn izable roots of th is su rgery have 
been m od ified  from  Elliot’s trep hination originally 
described  in 1909. While advances in this procedure 
with antimetabolites have improved  surgical outcomes, 
subconjunctival ſ ltration still resu lts in a signiſ cant 
number of complications and is prone to surgical failure.[13]
One major drawback to current techniques is the lack 
of standardization. In trabeculectomy, tension of the ƀap 
suture (which ultimately regulates ƀow) is d ictated  by a 
subjective process rendering it poorly reproducible even 
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Glaucoma surgery is ripe for innovation. In the last few years, there has been a substantial increase in the 
number of devices approaching commercialization. While not all that is new is necessarily good , the role 
of these devices in changing glaucoma surgery is equally important in terms of both success and  failure. 
Trabeculectomy, the most commonly performed incisional ſ ltration surgery for glaucoma, is subjective by 
nature and certainly has risks. As devices aim to standardize glaucoma surgery, speciſ cally subconjunctival 
ſ ltration surgery, predictability and in turn safety should theoretically improve. This may allow the glaucoma 
surgeon to intervene earlier in the d isease process, prevent more advanced  vision loss and  potentially 
decrease the burden of medications.
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in the same surgeon’s hands. Even tube shunt surgery 
requ ires intraoperative mod iſ cations decreasing the 
efſ ciency of these devices as well as the reproducibility 
of the surgery. Alterations such as tying off nonvalved  
tubes, leaving viscoelastics in the anterior chamber, 
and  placing ripcord  sutures represent variability in this 
surgery. In addition, even the length of tubing attached to 
the plate may vary in similar surgeries. Safety and  better 
efſ cacy can be achieved with improved standard ization 
and  reproducibility in glaucoma surgery.
Fortunately, glaucoma su rgery is moving tow ard 
safer, more reproducible and  microinvasive op tions 
comparable to what was seen with cataract surgery with 
the advent of phacoemulsiſ cation. Phacoemulsiſ cation 
changed  the w ay cataract su rgery w as p erform ed 
beyond the surgery itself. It created  a need  for foldable 
intraocular lenses, which were eventually developed . It 
allowed for the management of complex cases in a safer 
and  more reproducible way. As incision size remained  
small, complications associated  with larger penetrating 
incisions were decreased . Most notably, patients were 
treated  earlier in  d isease. Since the risks of su rgery 
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w ere low er w ith  phacoemulsification, su rgeons d id  
not wait until cataracts were virtually blind ing prior 
to recommending intervention. This proved  beneſ cial 
for both patients and  the society. Costeffectiveness 
analyses on cataract surgery, performed in 2012, show a 
4500% return on investment for ſ rsteye cataract surgery 
over 13 years.[4] Earlier intervention in d isease requires 
that the procedure be safer, but not necessarily more 
efſ cacious than traditional surgeries. It is imperative that 
we consider this issue when evaluating novel glaucoma 
procedures.
Early intervention in glaucoma is more prudent as 
compared  to cataract surgery. When visual ſ eld  is lost, 
it is generally unrecoverable. This is why safer glaucoma 
surgery can shape the future of how we treat glaucoma. 
In stead  of relying on  m ed ications, a  sh ift  tow ard  
glaucoma surgery at earlier points in the course of the 
d isease may occur probably decreasing the overall cost 
of treatment as compared  to medications.[5] Considering 
the myriad  of adverse effects of topical medications, it 
may be time to critically reconsider the present approach 
in the management of early glaucoma.[6]
We must, however, be cau tious as we learn more 
about these procedures. Not everything that is new is 
effective nor necessarily safe. The following 510 years 
will be very inƀuential to how the landscape of glaucoma 
surgery may change. Several novel glaucoma devices 
will have ſ nished their FDA trials. Once these devices 
become universally available, the next step of our journey 
can be commenced; comparative stud ies between novel 
techniques and our gold standards for glaucoma surgery. 
With patient quality of life and  costburden in mind , 
we may be able to justify early intervention for this 
progressive d isease.
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